Updated: 30th June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
Why ISO 15223-1:2025 Matters for Medical Device Labelling
Under the EU MDR, symbols on labels and IFUs aren’t decoration – they’re regulated information. MDR Annex I (Information supplied with the device) sets expectations for label content and how symbol meanings must be handled, especially where symbols aren’t universally recognised or harmonised.
So when the symbol set shifts, your artwork can quietly drift out of alignment with MDR expectations – and auditors love visible, objective findings.
This guide explains what changed in ISO 15223-1:2025 (formally, many teams will encounter it as ISO 15223-1:2021 + A1:2025), why the EC REP → EU REP change matters, and how to update labels, IFUs, and technical documentation without creating a change-control mess.
ISO 15223-1 focuses specifically on symbols used with information supplied by the manufacturer. It should be read alongside broader medical device labelling requirements under the EU MDR, including UDI, IFUs, manufacturer details, authorised representative information and traceability requirements.
For a broader overview of labels, IFUs, UDI and labelling best practices, read our Medical Device Labelling Guide.
Need an Introduction to the EU MDR?
This article explains ISO 15223-1 medical device symbols and their role in EU MDR compliance. If you're looking for a complete overview of the Medical Device Regulation, including classification, GSPRs, labelling, technical documentation, UDI, CE marking and post-market obligations, read our Complete Guide to the EU MDR.
Looking for a Complete Guide to Medical Device Labelling?
Understanding ISO 15223-1 symbols is only one part of creating compliant medical device labels. For a comprehensive guide covering EU MDR labelling requirements, mandatory label content, Instructions for Use (IFUs), UDI, language requirements, common non-conformities and best practices, explore our Medical Device Labelling Under the EU MDR & IVDR Guide.
What is ISO 15223-1?
ISO 15223-1 is the go-to standard for symbols used with medical devices (specifically: symbols to be used with information supplied by the manufacturer). It’s widely used to standardise label/IFU symbols so users (and regulators) aren’t forced to decode your packaging like it’s an escape room.
Official listing: the base standard is ISO 15223-1:2021.
Why auditors care:
- Symbols are high-visibility. They’re on packaging, labels, IFUs – everywhere.
- Symbols link directly to regulated requirements for “information supplied with the device” under MDR.
- Symbols must be consistent across your label, IFU symbol legend, and technical documentation (including your GSPR evidence trail).
What changed in ISO 15223-1:2025 (Amendment A1)
At a practical level, the 2025 amendment exists because the regulatory world moved on, but labelling systems… didn’t. “EC” language has been hanging around like a ghost of directives past.
BSI summarises the impact bluntly: BS EN ISO 15223-1:2021+A1:2025 supersedes the original version and is required for regulatory declarations of conformity (i.e., it’s not just a “nice to have”).
The most talked-about update is the authorised representative symbol wording/meaning shift:
- EC REP (old) → EU REP (new)
The headline update: EC REP → EU REP
What was the EC REP symbol?
Historically, EC REP was used to indicate the European Community authorised representative. It became a habit. And like all habits, it fossilised into artwork templates, label libraries, and “approved” packaging that nobody wants to reopen.
What is the EU REP symbol now?
The amended standard updates the authorised representative symbol to reflect EU terminology: EU REP.
Various explainers are floating around, but the core point is consistent: the “EC REP” designation is being replaced by “EU REP”.
Why this matters in audits (the uncomfortable truth)
Because this is the kind of finding an auditor can spot from across the room.
It also creates document inconsistency risk:
Label shows EC REP
IFU legend explains EU REP
DoC references an updated standard
Technical documentation still contains legacy symbol tables
That’s how you get a nonconformity that’s painful precisely because it’s so avoidable.
Which products are affected by the ISO 15223-1:2025 update
You’re in the impact zone if any of the below are true:
- You place devices on the EU market under MDR, and you use an authorised representative symbol.
- You’re a non-EU manufacturer, and your labels/IFUs include authorised representative details (MDR expects AR information to be supplied where applicable).
- You have shared label templates across multiple SKUs or product families (one template change = portfolio-wide consequence).
Even for “legacy” products under transitional arrangements, labels are still reviewed during surveillance activity, and symbols are easy audit targets.
Medical device labelling symbols beyond EU REP
The EU REP update is the headline, but it’s rarely the only issue. Once you start looking, you often find:
- Obsolete symbol variants are still used on older packaging
- Custom icons nobody can define consistently
- Symbols present on packaging but missing (or inconsistently explained) in IFU symbol legends
MDR’s logic is simple: if a symbol isn’t clearly “internationally recognised” (or otherwise appropriately supported), its meaning must be explained in the information supplied with the device.
This is where companies get caught: not because they used symbols, but because they used symbols sloppily.
Need a Detailed Breakdown of EU MDR Labelling Requirements?
This guide provides an overview of medical device labelling. If you're looking for a more detailed explanation of the mandatory requirements under Annex I, Chapter III of the EU MDR, including label content, Instructions for Use (IFUs), language requirements and common compliance pitfalls, read our Medical Device Labelling Requirements Explained.
Impact on IFUs, packaging, and technical documentation
A symbol change triggers a documentation chain reaction. In a controlled system, it should look like this:
- Label/packaging artwork update (symbol corrected)
- IFU symbol legend update (definitions match what’s on-pack)
- Change control record (why changed, what impacted, what didn’t)
- Technical documentation alignment (label specs, symbol tables, evidence references)
If you update the label but forget the IFU legend, you’ve just created a contradiction. If you update the IFU legend but forget the outer carton, you’ve created a contradiction.
When do you need to update your labels?
Use this audit-proof decision framework:
- Are you using “EC REP” anywhere? If yes: flag it. This is the quickest win.
- Are you a non-EU manufacturer selling into the EU? If yes, your AR information and how it’s presented must be correct and consistent with MDR expectations.
- Is a review event approaching? Surveillance audit, recertification, NB technical documentation sampling, labelling refresh, IFU update, packaging supplier change – any of these are a sane trigger to fix symbols proactively. This is usually a controlled labelling change, not a product redesign. But it still needs proper documentation discipline.
Common medical device labelling mistakes seen in audits
These are the repeat offenders:
- Mixing EC REP on packaging with EU terminology elsewhere
- Updating IFUs but not packaging (or the reverse)
- Treating a symbol change as “too minor” for change control
- No clear rationale or impact assessment (what changed, why, and what was checked)
- Out-of-sync symbol legends across language variants[Image placeholder
How to approach ISO 15223-1:2025 compliance practically
Here’s the sane, low-drama approach:
1) Inventory everything that carries symbols
Labels, IFUs, cartons, quick-start guides, eIFU PDFs, website “label downloads”, distributor overlabels – all of it.
2) Identify authorised representative references
Look for text and symbols. Some products have one but not the other.
3) Update symbol usage per the amended standard
If your organisation adopts BS EN ISO 15223-1:2021+A1:2025, treat it as your controlled reference and align artwork accordingly.
4) Build a tight change-control pack
Include the:
- Reason for change (standard amendment/terminology update)
- Affected SKUs/artwork IDs
- Risk impact (typically low, but document it)
- Usability impact check (especially if you change accompanying text)
- Verification (proofs reviewed, symbol legend updated, translations checked)
5) Align your technical documentation
Update the:
- Label specs / artwork references
- IFU symbol legend tables
- Any “symbols used” section in your technical file
- Any declarations or standard references that cite the updated standard set
6) Brief relevant parties
If you’re working with an NB, an AR, or a critical distributor, short proactive comms can prevent confusion later (“Yes, this is why the label changed; no, the device didn’t.”).
How Patient Guard helps with labelling compliance
Patient Guard’s value here isn’t “we can tell you EC REP is old”. You already know that now.
The value is doing the controlled, audit-proof implementation including:
- ISO 15223-1 symbol gap reviews across label/IFU packs
- Portfolio-wide artwork audits (including template-driven families)
- Change impact assessments and change-control documentation packs
- NB readiness checks for “information supplied with the device” under MDR Annex I, Chapter III
Conclusion
ISO 15223-1:2025 is not theoretical. It’s printed on your packaging.
The EC REP → EU REP update is:
- Visible (on labels),
- Verifiable (easy to prove),
- And avoidable (easy to fix if you do it properly).
Treat it as a controlled labelling update: update the symbol, align the IFU legend, document the change, and keep your technical documentation consistent. Contact Patient Guard for an ISO 15223-1:2025 labelling compliance review before your next audit cycle. Book a free consultation today.
Frequently Asked Questions About ISO 15223-1:2025
The key practical change most teams feel is the authorised representative symbol shift from EC REP to EU REP, alongside broader symbol/terminology clean-up aligned to the current regulatory landscape. (BSI Knowledge)
If your labelling uses the authorised representative symbol and you’re aligning to the amended standard set, yes – you should update to the current designation to avoid clear, preventable inconsistencies. (MedEnvoy)
As soon as practical – ideally ahead of a surveillance audit, technical documentation sampling, or artwork refresh. The earlier you do it, the less it feels like reactive CAPA theatre.
Usually, yes. Anywhere the symbol appears or is explained should remain consistent (label, IFU symbol legend, packaging, and technical documentation). MDR expects symbol meaning and label info to be handled coherently.
They look for objective consistency: correct label info, correct symbol use, and alignment between label/IFU and technical documentation under MDR Annex I requirements.
Yes – including symbol audits, IFU legend alignment, and change-control packs that stand up in NB or competent authority review.
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to ISO 15223-1, medical device symbols and labelling requirements.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| International Organization for Standardization (ISO) | ISO 15223-1:2021 – Medical Devices – Symbols to Be Used with Information to Be Supplied by the Manufacturer – Part 1: General Requirements | Defines the internationally recognised symbols used on medical device labels, packaging and accompanying information. Amendment 1:2025 introduces updates including the revised Authorised Representative symbol and additional terminology. :contentReference[oaicite:0]{index=0} |
| European Union | Regulation (EU) 2017/745 on Medical Devices (MDR) | Requires manufacturers to provide appropriate information with medical devices and establishes the legal framework for labelling, symbols and information supplied by the manufacturer. |
| International Organization for Standardization (ISO) | ISO 20417:2026 – Medical Devices – Information to Be Supplied by the Manufacturer | Specifies the information manufacturers must supply with medical devices, including labels, packaging, markings and Instructions for Use, complementing ISO 15223-1 by defining what information must be provided. |
| European Commission | MDCG Endorsed Documents and Other Guidance | Provides official Medical Device Coordination Group guidance supporting implementation of MDR labelling requirements, including guidance relating to symbols, information supplied by the manufacturer and UDI. |
| European Union | Commission Implementing Decision (EU) 2026/1313 | Updates the references to harmonised standards under the IVDR, including EN ISO 15223-1:2021/A1:2025, and provides the transition period for implementation of the amended symbol requirements. :contentReference[oaicite:1]{index=1} |
| U.S. Food and Drug Administration (FDA) | FDA Recognized Consensus Standard – ISO 15223-1:2021 Including Amendment 1:2025 | Confirms that the FDA recognises ISO 15223-1:2021 including Amendment 1:2025 as a consensus standard and sets out the transition arrangements for U.S. regulatory submissions. :contentReference[oaicite:2]{index=2} |
Medical device symbol requirements continue to evolve through amendments to international standards and regulatory recognition. Manufacturers should always consult the latest published legislation, recognised standards and official guidance when reviewing and updating device labels, packaging and accompanying information.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
